Humacyte (NASDAQ:HUMA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA) from a strong sell rating to a sell rating in a research note published on Saturday morning.

Several other research analysts also recently commented on HUMA. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. Benchmark raised their target price on Humacyte to $2.00 and gave the company a “speculative buy” rating in a report on Monday, June 1st. BTIG Research reiterated a “buy” rating and issued a $2.00 price target on shares of Humacyte in a research note on Tuesday, July 28th. TD Cowen lowered their price target on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a report on Wednesday, June 17th. Finally, HC Wainwright upped their price objective on Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Humacyte presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.25.

Humacyte Price Performance

HUMA stock opened at $0.69 on Friday. The company’s 50-day moving average price is $0.89 and its two-hundred day moving average price is $0.92. The firm has a market cap of $153.04 million, a P/E ratio of -1.21 and a beta of 2.54. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. Humacyte has a 12 month low of $0.55 and a 12 month high of $2.76.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $0.49 million during the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. On average, analysts anticipate that Humacyte will post -0.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Humacyte news, Director Kathleen Sebelius bought 56,818 shares of Humacyte stock in a transaction on Tuesday, May 19th. The shares were purchased at an average cost of $0.88 per share, with a total value of $49,999.84. Following the acquisition, the director directly owned 148,025 shares of the company’s stock, valued at $130,262. The trade was a 62.30% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Shamik J. Parikh sold 45,887 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the transaction, the insider directly owned 272,713 shares of the company’s stock, valued at $245,441.70. The trade was a 14.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.10% of the company’s stock.

Institutional Trading of Humacyte

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Group AG increased its stake in shares of Humacyte by 48.8% in the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock valued at $2,862,000 after buying an additional 976,275 shares during the period. United Asset Strategies Inc. boosted its holdings in Humacyte by 13.5% in the fourth quarter. United Asset Strategies Inc. now owns 209,608 shares of the company’s stock valued at $201,000 after acquiring an additional 25,000 shares during the last quarter. SG Americas Securities LLC raised its holdings in Humacyte by 50.3% during the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after purchasing an additional 11,411 shares during the last quarter. R Squared Ltd lifted its position in shares of Humacyte by 140.5% in the 1st quarter. R Squared Ltd now owns 62,911 shares of the company’s stock worth $38,000 after purchasing an additional 36,758 shares during the period. Finally, Private Advisor Group LLC boosted its stake in shares of Humacyte by 48.3% in the 1st quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock valued at $505,000 after purchasing an additional 271,222 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.